BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for BioDelivery Sciences International, Inc. (BDSI)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
5 days ago | Zacks Investment Research
a week ago | Benzinga
a week ago | Zacks Investment Research
a week ago | GlobeNewsWire
a week ago | GlobeNewsWire
2 weeks ago | Zacks Investment Research
a month ago | The Motley Fool
3 months ago | Zacks Investment Research
3 months ago | GlobeNewsWire
3 months ago | Zacks Investment Research